Kringle Pharma (TSE:4884) Moat Score: 0/10 (As of Jul. 11, 2026)


TSE:4884 Kringle Pharma Inc TSE:4884
44 GF Score
Price 円332.00
GF Value 円493.27
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Moat Score?

Kringle Pharma has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Kringle Pharma has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Kringle Pharma might have No Moat - No discernible moat.

Kringle Pharma  (TSE:4884) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Kringle Pharma Moat Score Related Terms

TSE:4884
44GF Score
Kringle Pharma Inc TSE:4884
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円332.00 is trading 32.7% below its estimated GF Value™ of 円493.27. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • Moat Score: 0
  • GF Value™: 円493.27 vs. price of 円332.00 (32.7% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
44GF Score

Get the complete analysis for TSE:4884

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円332.00
Price
円493.27
GF Value